OBJECTIVE: Although the association between circulating levels of lipoprotein(a) [Lp(a)] and risk of coronary artery disease (CAD) and stroke is well established, its role in risk of peripheral arterial disease (PAD) remains unclear. Here, we examine the association between Lp(a) levels and PAD in a large prospective cohort. To contextualize these findings, we also examined the association between Lp(a) levels and risk of stroke and CAD and studied the role of low-density lipoprotein as an effect modifier of Lp(a)-associated cardiovascular risk. METHODS AND RESULTS: Lp(a) levels were measured in apparently healthy participants in the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort. Cox regression was used to quantify the association between Lp(a) levels and risk of PAD, stroke, and CAD outcomes. During 212 981 person-years at risk, a total of 2365 CAD, 284 ischemic stroke, and 596 PAD events occurred in 18 720 participants. Lp(a) was associated with PAD and CAD outcomes but not with ischemic stroke (hazard ratio per 2.7-fold increase in Lp(a) of 1.37, 95% CI 1.25-1.50, 1.13, 95% CI 1.04-1.22 and 0.91, 95% CI 0.79-1.03, respectively). Low-density lipoprotein cholesterol levels did not modify these associations. CONCLUSIONS: Lp(a) levels were associated with future PAD and CAD events. The association between Lp(a) and cardiovascular disease was not modified by low-density lipoprotein cholesterol levels.
OBJECTIVE: Although the association between circulating levels of lipoprotein(a) [Lp(a)] and risk of coronary artery disease (CAD) and stroke is well established, its role in risk of peripheral arterial disease (PAD) remains unclear. Here, we examine the association between Lp(a) levels and PAD in a large prospective cohort. To contextualize these findings, we also examined the association between Lp(a) levels and risk of stroke and CAD and studied the role of low-density lipoprotein as an effect modifier of Lp(a)-associated cardiovascular risk. METHODS AND RESULTS: Lp(a) levels were measured in apparently healthy participants in the European Prospective Investigation of Cancer (EPIC)-Norfolk cohort. Cox regression was used to quantify the association between Lp(a) levels and risk of PAD, stroke, and CAD outcomes. During 212 981 person-years at risk, a total of 2365 CAD, 284 ischemic stroke, and 596 PAD events occurred in 18 720 participants. Lp(a) was associated with PAD and CAD outcomes but not with ischemic stroke (hazard ratio per 2.7-fold increase in Lp(a) of 1.37, 95% CI 1.25-1.50, 1.13, 95% CI 1.04-1.22 and 0.91, 95% CI 0.79-1.03, respectively). Low-density lipoprotein cholesterol levels did not modify these associations. CONCLUSIONS: Lp(a) levels were associated with future PAD and CAD events. The association between Lp(a) and cardiovascular disease was not modified by low-density lipoprotein cholesterol levels.
Authors: Jill J F Belch; Eric J Topol; Giancarlo Agnelli; Michel Bertrand; Robert M Califf; Denis L Clement; Mark A Creager; J Donald Easton; James R Gavin; Philip Greenland; Graeme Hankey; Peter Hanrath; Alan T Hirsch; Jürgen Meyer; Sidney C Smith; Frank Sullivan; Michael A Weber Journal: Arch Intern Med Date: 2003-04-28
Authors: L Norgren; W R Hiatt; J A Dormandy; A T Hirsch; M R Jaff; C Diehm; I Baumgartner; J J F Belch Journal: Eur J Vasc Endovasc Surg Date: 2010-06-15 Impact factor: 7.069
Authors: Jemma C Hopewell; Robert Clarke; Sarah Parish; Jane Armitage; Mark Lathrop; Jorg Hager; Rory Collins Journal: Circ Cardiovasc Genet Date: 2011-01-20
Authors: Corey A Scipione; Sera E Sayegh; Rocco Romagnuolo; Sotirios Tsimikas; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky Journal: J Lipid Res Date: 2015-10-16 Impact factor: 5.922
Authors: Constantine E Kosmas; Delia Silverio; Andreas Sourlas; Richard Peralta; Peter D Montan; Eliscer Guzman; Mario J Garcia Journal: Ann Transl Med Date: 2019-09
Authors: Monica L Bertoia; Jennifer K Pai; Jun-Hee Lee; Adam Taleb; Michel M Joosten; Murray A Mittleman; Xiaohong Yang; Joseph L Witztum; Eric B Rimm; Sotirios Tsimikas; Kenneth J Mukamal Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: Nishant P Shah; Neha J Pajidipati; Robert W McGarrah; Ann Marie Navar; Sreekanth Vemulapalli; Michael A Blazing; Svati H Shah; Adrian F Hernandez; Manesh R Patel Journal: Am J Cardiol Date: 2020-04-07 Impact factor: 2.778